The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow up.
Adding toripalimab to standard first-line chemotherapy significantly prolonged survival in patients with advanced esophageal squamous cell carcinoma.
The 2-year actuarial rate of local recurrence was 4.8%.
There was a positive association between more frequent antibiotic use and colorectal cancer overall.
Reductions in mortality were seen in association with ACE inhibitors, beta-blockers, and thiazide diuretics.
The association was stronger for dietary sources of vitamin D than supplemental vitamin D.
Barrett’s esophagus appears to originate from the gastric cardia.
Authors say this association may be contributing to increasing incidence rates of colorectal cancer in younger adults.
The approval was based on data from the double-blind, placebo-controlled ClarIDHy study.
Frequency of alcohol consumption may be more important than the amount of alcohol consumed.
The objective response rate was 23.1%, and the disease control rate was 84.3%.
The study showed no significant differences in outcomes by age.
The median duration of response was 10.8 months.
The overall response rate was 7.8%, and the disease control rate was 65%.
Patients with liver metastases did not respond to checkpoint inhibitors.
The progression-free survival and overall survival at 1 year were 61% and 85%, respectively.
Segments with incomplete resection have increased risk for any metachronous neoplasia, advanced neoplasia.
The chemoradiotherapy regimen was more effective than radiotherapy alone.
The VOYAGER study did not meet its primary endpoint.
The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.